Optinose Inc (OPTN)

Apr 29, 2025, 12:35 PM EDT - 5 weeks ago

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

Mar 21, 2025, 9:40 AM EDT - 2 months ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders

BECN

Mar 19, 2025, 9:45 PM EDT - 2 months ago

Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call

Mar 19, 2025, 9:25 PM EDT - 2 months ago

Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)

Jan 15, 2025, 7:00 AM EST - 5 months ago

Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million

Dec 26, 2024, 7:00 AM EST - 5 months ago

Optinose Announces 1-for-15 Reverse Stock Split

Dec 2, 2024, 3:53 PM EST - 6 months ago

Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 12:47 PM EST - 7 months ago

OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 7 months ago

Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights

Nov 5, 2024, 4:30 PM EST - 7 months ago

Optinose Announces Reporting Date for Third Quarter 2024 Financial Results

Oct 16, 2024, 4:05 PM EDT - 8 months ago

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 7, 2024, 4:59 PM EDT - 8 months ago

Optinose Appoints Terry Kohler as Chief Financial Officer

Sep 5, 2024, 9:00 AM EDT - 9 months ago

New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery

Aug 26, 2024, 9:00 AM EDT - 10 months ago

Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 11, 2024, 7:17 AM EDT - 10 months ago

OptiNose, Inc. (OPTN) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 8:30 AM EDT - 11 months ago

Optinose Announces Reporting Date for Second Quarter 2024 Financial Results

Jun 27, 2024, 7:00 AM EDT - 1 year ago

Expanded Access to XHANCE with Addition to National Commercial Formularies

May 17, 2024, 8:55 PM EDT - 1 year ago

OptiNose, Inc. (OPTN) Q1 2024 Earnings Call Transcript

May 17, 2024, 12:00 PM EDT - 1 year ago

Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 14, 2024, 7:00 AM EDT - 1 year ago

Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights

May 10, 2024, 2:56 PM EDT - 1 year ago

Optinose Announces Reporting Date for First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 1 year ago

Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million

Apr 4, 2024, 4:01 PM EDT - 1 year ago

Optinose to Present at the Needham Virtual Healthcare Conference

Mar 15, 2024, 3:34 PM EDT - 1 year ago

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Mar 7, 2024, 9:14 AM EST - 1 year ago

OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 7:00 AM EST - 1 year ago

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Feb 29, 2024, 4:40 PM EST - 1 year ago

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

Jan 18, 2024, 12:00 PM EST - 1 year ago

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Dec 6, 2023, 7:00 AM EST - 1 year ago

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

Nov 22, 2023, 9:00 AM EST - 1 year ago

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 9, 2023, 10:04 AM EST - 1 year ago

OptiNose, Inc. (OPTN) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 7:00 AM EST - 1 year ago

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

Sep 22, 2023, 9:01 AM EDT - 1 year ago

Optinose to Present at the 2023 Cantor Global Healthcare Conference

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

Aug 1, 2023, 6:58 PM EDT - 2 years ago

OptiNose: The Worst Has Been Avoided (Rating Upgrade)

Jul 27, 2023, 7:00 AM EDT - 2 years ago

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

Jun 16, 2023, 4:08 PM EDT - 2 years ago

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 1:00 PM EDT - 2 years ago

Optinose to Present at the Jefferies Healthcare Conference

May 11, 2023, 5:57 PM EDT - 2 years ago

OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript

May 11, 2023, 7:00 AM EDT - 2 years ago

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

May 1, 2023, 4:30 PM EDT - 2 years ago

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

Mar 7, 2023, 2:22 PM EST - 2 years ago

OptiNose, Inc. (OPTN) Q4 2022 Earnings Call Transcript

Mar 7, 2023, 7:00 AM EST - 2 years ago

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

Feb 28, 2023, 4:30 PM EST - 2 years ago

Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results

Jan 31, 2023, 7:00 AM EST - 2 years ago

Optinose Announces CEO Transition and Business Update

Dec 15, 2022, 4:30 PM EST - 2 years ago

Optinose Appoints Paul Spence as Chief Commercial Officer

Dec 9, 2022, 8:00 AM EST - 2 years ago

Optinose Announces Departure of Acting Chief Financial Officer